Regeneron Pharmaceuticals Inc (REGN) reports a 3% revenue increase, driven by robust sales of Dupixent and strategic pipeline developments, despite competitive pressures and rising R&D expenses.

The autonomous forklift market offers key growth opportunities driven by labor shortages and e-commerce demands for 24/7 operations. Major trends include transitioning to vision-guided, infrastructure ...

Regeneron (REGN) reported $3.88 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 2.5%. EPS of $11.44 for the same period compares to $12.07 a year ago.

A federal judge dismissed some of Luigi Mangione’s charges on Friday, preventing prosecutors from seeking the death penalty.